Pharmacogenomics

Genetic Testing Market to Reach $28.24 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Meticulous Research®

Retrieved on: 
Monday, March 20, 2023
Glaucoma, DNA, Ventricular septal defect, Prevalence, Impact, Viral Research and Diagnostic Laboratories, Parent, Hospital, Pharmacogenomics, COVID-19, Cancer, Down syndrome, Genetic testing, Diagnosis, Genomics, Hemoglobinopathy, Disorder, Government, PerkinElmer, Fragile X syndrome, MUFG Americas Holdings Corporation, Thermo Fisher Scientific, Patient, Laboratory, Risk, Developed country, Preimplantation genetic diagnosis, Investment, Labcorp, Consumables, Cystic fibrosis, Carrier, Hospital Clinic Manuel Quintela, Association for Molecular Pathology v. Myriad Genetics, Inc., Rare, Illumina, Inc., Geography, Pharmaceutical industry, Dietary supplement, Chromosome, Prenatal development

Genetic testing is done to look at changes in the DNA, sometimes called variants or mutations, that can lead to chronic diseases.

Key Points: 
  • Genetic testing is done to look at changes in the DNA, sometimes called variants or mutations, that can lead to chronic diseases.
  • Genetic testing is performed for different reasons, including pre-symptomatic and predictive testing, pharmacogenetics, diagnostic testing, carrier testing, prenatal testing, preimplantation testing, and newborn screening.
  • Genetic testing has applications in different areas of healthcare and has various advantages, such as determining the likelihood of parents passing the genetic mutation to their offspring.
  • Quick Buy – Genetic Testing Market Research Report: https://www.meticulousresearch.com/Checkout/33822956
    Based on end user, in 2023, the hospitals & clinics segment is expected to account for the largest share of this market.

Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company

Retrieved on: 
Monday, February 13, 2023
Toxicology, Laboratory, Pharmacogenomics, Celltech, LSM, Cyprus Securities and Exchange Commission, Pathology, National Health Laboratory Service, Genetic testing, STAT, Niche market, Earnout

FREEHOLD, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has acquired a 40% interest in Laboratory Services MSO, LLC (“LSM”), a premier clinical diagnostics and reference laboratory. Headquartered in Costa Mesa, California, LSM provides a broad portfolio of diagnostic tests including drug testing, toxicology, pharmacogenetics, and a broad array of test services, from general bloodwork to anatomic pathology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory. It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry. LSM has completed over 600,000 tests since inception and currently has two operational locations in California.

Key Points: 
  • FREEHOLD, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has acquired a 40% interest in Laboratory Services MSO, LLC (“LSM”), a premier clinical diagnostics and reference laboratory.
  • Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more.
  • LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory.
  • It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry.

Labroots to Host 6th Annual Drug Discovery & Development Online Event, February 22, 2023

Retrieved on: 
Thursday, February 16, 2023
RAGE, GPCR, University of Western Australia, Networking hardware, Q&A, Pharmacology, University, Biomedicine, Drug development, Drug discovery, Sartorius, Research, Therapy, PDX, Doctor of Philosophy, Medical research, Labroots, Harry Perkins Institute of Medical Research, Advantage Business Media, Spatial analysis, Environment, BLI, Pharmaceutical industry, Pharmacogenomics, News, New Method College

YORBA LINDA, Calif., Feb. 16, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, is hosting its Drug Discovery & Development virtual event on February 22, 2023. The 6th annual free event in the Drug Discovery & Development Virtual Event Series, is a dynamic reputable forum bringing together thousands of innovative research scholars, clinicians and scientists across leading, medical, industry, and academic professions from around the world.

Key Points: 
  • YORBA LINDA, Calif., Feb. 16, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, is hosting its Drug Discovery & Development virtual event on February 22, 2023.
  • Drug Discovery & Development 2023 promises to deliver on its commitment of bringing emerging topics to the forefront of the scientific community such as Improved Models in Drug Discovery and Preclinical Development, New Methods in PK/PD and Pharmacogenomics, and Biomarker Applications in Clinical Development.
  • Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development.
  • You can now also join our Drug Discovery, Development, & Therapeutics professional networking group on LinkedIn!

Providence Therapeutics Appoints Robert Georgantas, Ph.D. as President and Chief Technology Officer

Retrieved on: 
Wednesday, February 1, 2023
AbbVie, RNA, Johns Hopkins School of Medicine, MBA, Information Holdings Inc., Immunology, Illinois Institute of Technology, PTX-COVID19-B, GRC, COVID-19, Biomarker, Cancer, Johns Hopkins University, Zeneca, Vaccine, National Center for Advancing Translational Sciences, Therapy, Infection, Providence, Drug discovery, Algorithm, Faculty, RNA transfection, MedImmune, Cell biology, Research, Pharmaceutical industry, Pharmacogenomics

CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced the appointment of Robert Georgantas III, Ph.D., as President and chief technology officer (CTO).

Key Points: 
  • CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced the appointment of Robert Georgantas III, Ph.D., as President and chief technology officer (CTO).
  • “Robert’s experience in drug discovery, clinical development, and management at the executive level across several biotech and large pharmaceutical companies will be invaluable as we continue advancing our pipeline of mRNA vaccines,” said Brad Sorenson, MBA, chief executive officer of Providence Therapeutics.
  • He additionally contributed to clinical development and medical affairs activities, participating in the design and statistical analysis of multiple clinical studies.
  • Dr. Georgantas received his Ph.D. at the Johns Hopkins University School of Medicine and his master’s degree in Cellular Biology at the Illinois Institute of Technology.

Nest Genomics Closes $8.5 Million Seed Financing to Bring Genomics into Mainstream Patient Care

Retrieved on: 
Tuesday, January 10, 2023
Technology, Finance, Consulting, Genetics, Other Technology, Health Technology, Professional Services, Software, Health, Disease, Genetic testing, Adoption of electronic medical records in U.S. hospitals, Public health, Y Combinator, American College, General partnership, Nucleic acid sequence, Polygene, Pediatrics, Scores, Genomics, American College of Medical Genetics and Genomics, Pharmacogenomics, Health, Cancer, Electronic health record, Genetic counseling, EMR, Patient, Medicine, Medical genetics, Pharmaceutical industry, Nest, Invitae

Nest is an end-to-end solution designed to help health systems, clinics, pharmaceutical companies, and payors launch and scale longitudinal genomic programs.

Key Points: 
  • Nest is an end-to-end solution designed to help health systems, clinics, pharmaceutical companies, and payors launch and scale longitudinal genomic programs.
  • The Electronic Medical Records (EMR)-integrated platform allows for the seamless incorporation of genomics into clinical practice within existing workflows, including clinical decision support to help providers create patient care plans based on the latest clinical guidelines and patient information.
  • The solution also includes patient engagement tools that empower patients to understand and manage their genetic information over time.
  • To realize this potential, we must address the major challenges of incorporating genetic information into provider workflows and patient care,” said Moran Snir, Nest Genomics Co-Founder and CEO.

Nicklaus Children's Hospital Brings Real-time Genomic Decision Support to Patient Care with the ActX Service

Retrieved on: 
Wednesday, January 11, 2023
Partnership, Nicklaus Children's Hospital, Health, Precision medicine, MD, Children's Hospital, Jack Nicklaus, Millennium, Biobank, Genetic testing, EHR, Risk, Patient, Pathology, Child, Physician, Safety, Pharmacogenomics, Workflow, Genetics, Hospital, Medicine, Pharmaceutical industry, Cerner

MIAMI, Jan. 11, 2023 /PRNewswire-PRWeb/ -- Nicklaus Children's Hospital, South Florida's only licensed specialty hospital exclusively for children, is taking a major step forward in personalizing patient care using genetics by using the ActX Genomic Decision Support platform. The ActX service is connected into the Oracle Cerner Electronic Health Record to provide physicians with real-time alerts based on the patient's genetics, all within normal physician workflow.

Key Points: 
  • Nicklaus Children's Hospital, South Florida's only licensed specialty hospital exclusively for children, is taking a major step forward in personalizing patient care using genetics by using the ActX Genomic Decision Support platform.
  • MIAMI, Jan. 11, 2023 /PRNewswire-PRWeb/ -- Nicklaus Children's Hospital, South Florida's only licensed specialty hospital exclusively for children, is taking a major step forward in personalizing patient care using genetics by using the ActX Genomic Decision Support platform.
  • "We are excited to partner with Nicklaus Children's Hospital as they bring precision medicine to patient care at the bedside or in the clinic.
  • With ActX Genomic Decision Support connected directly into their Cerner (Millennium) EHR, ActX will provide seamless point of care decision support to Nicklaus's physicians.

James G. Krueger MD, Ph.D., is recognized by Continental Who's Who

Retrieved on: 
Thursday, December 29, 2022
Inflammatory bowel disease, Internal medicine, Pharmacogenomics, Rockefeller University, Hidradenitis suppurativa, Trial of the century, Patient, Psoriasis, Education, Continental, Cooking, Laboratory, Tissue, Immune system, Pinnacle, Innovation, Rheumatoid arthritis, Knowledge, Skin, Diagnosis, Cell biology, T helper 17 cell, Medicine, Inflammation, Degenerative disease, Weill Cornell Medicine, Gene expression, Bachelor, Therapy, Secondary research, Head, Science, American Board of Dermatology, Physician, Research, ABD, Princeton University, American Board of Commissioners for Foreign Missions, Vaccine, Pharmaceutical industry, Dermatology, Virology

NEW YORK, Dec. 29, 2022 /PRNewswire/ -- James G. Krueger MD, Ph.D., is being recognized by Continental Who's Who as a Top Pinnacle Member for his excellence as a Dermatologist at Rockefeller University Hospital.

Key Points: 
  • NEW YORK, Dec. 29, 2022 /PRNewswire/ -- James G. Krueger MD, Ph.D., is being recognized by Continental Who's Who as a Top Pinnacle Member for his excellence as a Dermatologist at Rockefeller University Hospital.
  • Dr. Krueger earned his Bachelor's degree from Princeton University and a Ph.D. in Virology and Cell Biology from Rockefeller University.
  • Dr. Krueger uses psoriasis as a model to study inflammatory diseases that involve Th17 cells, a set of T cells.
  • According to Dr. Krueger, the laboratory conducts clinical research on patients with psoriasis vulgaris at The Rockefeller University Hospital.

US Survey Signals Big Shifts in Primary Care to Pharmacy & Clinic Settings as Consumers Seek Lower Medication and Healthcare Costs

Retrieved on: 
Wednesday, December 7, 2022
Research, Other Retail, Specialty, Public Policy, Government, Healthcare Reform, General Health, Pharmaceutical, Health, Retail, Science, Pharmacy, WKL, Trust, Elijah Cummings Lower Drug Costs Now Act, Lawyer, MD, Generation X, Workflow, Gen, PCP, Boomer, Center for Economic Studies (U.S. Census Bureau), Learning, Patient, Sale, Science, NO, Student, Research, Millennials, Hospital, Generation Z, FDA, Prescription, Woman, United States Census Bureau, Pharmacist, Multimedia, Thought, Safety, Education, Western world, Pharmacogenomics, Rx, Wolters Kluwer, Nursing, Practitioner, Risk, Health insurance, Medicine, Healthcare, Pharmaceutical industry, Risk management, Health

The survey reveals surprising inter-generational trends among Americans ready to extend their trust for care beyond traditional settings even to genomic testing if it means lower costs and better health outcomes.

Key Points: 
  • The survey reveals surprising inter-generational trends among Americans ready to extend their trust for care beyond traditional settings even to genomic testing if it means lower costs and better health outcomes.
  • View the full release here: https://www.businesswire.com/news/home/20221207005188/en/
    Pharmacy Next survey commissioned by Wolters Kluwer surveys consumers thoughts of retail pharmacies and drug costs.
  • According to the survey, titled Pharmacy Next: Health Consumer Medication Trends, Americans are bullish on the shift of primary care from the traditional primary care provider (PCP) office to newer models for care.
  • To staff these new settings, consumers would trust pharmacists (56%), nurse practitioners (55%) and physician assistants (50%) to provide healthcare and prescriptions if it meant lower costs.

Genomind Pharmacogenetic Population Health Tool Highlighted in American Journal of Managed Care and 22nd Population Health Colloquium

Retrieved on: 
Tuesday, November 15, 2022
Software, Managed Care, Data Management, Mental Health, Technology, Hospitals, Genetics, Science, Nursing, Practice Management, Other Science, Health, Analgesic, Health, Thomas Jefferson University, Probability, Population health, Prescription, Antiemetic, Colloquium, Pharmacy (shop), Disease, Monte Carlo, Pharmacogenomics, Moses Austin, American Journal, University, College, Doctor of Pharmacy, Risk, Patient, The American Journal of Managed Care, Health insurance, Pharmaceutical industry

An innovative population health approach from Genomind was highlighted in a peer-reviewed publication titled, Predicting Drug-Drug and Drug-Gene Interactions in a Community Pharmacy Population published in the latest issue of the American Journal of Managed Care (AJMC).

Key Points: 
  • An innovative population health approach from Genomind was highlighted in a peer-reviewed publication titled, Predicting Drug-Drug and Drug-Gene Interactions in a Community Pharmacy Population published in the latest issue of the American Journal of Managed Care (AJMC).
  • The article was co-authored by Stephen Saklad, PharmD, of the University of Texas at Austin and other Genomind colleagues.
  • Saklad and co-authors reported on an innovative, proprietary approach to population health, with the potential to widely prevent adverse drug events, improve outcomes, and save precious healthcare resources.
  • Dr. David Krause, Chief Medical Officer of Genomind Inc., and a co-author of the paper, presented the data at the recent 22nd Population Health Colloquium in Philadelphia.

GenXys Partners with Manchester University for Pharmacogenomics Education

Retrieved on: 
Tuesday, November 1, 2022
Awareness, Algorithm, Interview, CDSS, Population, Patient safety, Pharmacy, Doctor of Philosophy, Health, FCP, Population health, Legislation, Partnership, Genomics, Research, Pharmacogenomics, Student, Person, Doctor of Pharmacy, View, Clinical decision support system, Adoption, Education, Graduate certificate, Patient, Multimedia, University of Manchester, Solution, Insurance, Medicine, Pharmaceutical industry, MD, BC

VANCOUVER, BC, Nov. 1, 2022 /PRNewswire/ -- GenXys , the global leader in precision prescribing software with embedded pharmacogenetic (PGx) data, is teaming up with Manchester University ( MU ) for pharmacogenomics education.

Key Points: 
  • VANCOUVER, BC, Nov. 1, 2022 /PRNewswire/ -- GenXys , the global leader in precision prescribing software with embedded pharmacogenetic (PGx) data, is teaming up with Manchester University ( MU ) for pharmacogenomics education.
  • "As a national leader in pharmacogenetic and clinical education, Manchester University looks to partner with leading-edge technology companies that further the advancement of PGx for better health outcomes," says David Kisor, PharmD, FCP, Professor of Pharmaceutical Sciences and Pharmacogenomics, Director of Pharmacogenomics at MU.
  • https://www.genxys.com/
    Manchester University, in North Manchester and Fort Wayne, Ind., provides vibrant and transformative student experiences.
  • Manchester University respects the infinite worth of every individual and graduates persons of ability and conviction who draw upon their education and faith to lead principled, productive, and compassionate lives that improve the human condition.